Cambridge Cognition Share Discussion Threads

[jasperlachat] 11/10/2024 12:48

Thanks 40 Fathoms / they certainly don’t want me dropping my lot on the market. Trouble is we are now very much open to a ridiculously low ball offer.

[yump] 11/10/2024 12:48

I don’t mind overhangs, its the two areas I mentioned that bother me.

For the moment, I’m assuming its a handy collection of products yet to get significant traction.

However, concentration on reducing costs at this early stage makes me wonder wtf was going on previously.

If the spend resulted in rapid growth of a product, then fair enough.

Perhaps the market is very new but COG have been around for 8 years. Imo the state of the pharmaceutical market is irrelevant to the business - or should be if they’ve got a great product

[40 fathoms] 11/10/2024 12:19

Some seem to be misunderstanding the situation. The share price is dropping due to a sizable seller offloading their remaining shares in a tough market. We know who this seller is and how many shares they have left; they will be cleared out soon.

Anyone suggesting this is a lifestyle business doesn't understand Cambridge Cognition, the markets it operates in, or its market position.

Another point worth making is that the company is likely to signficantly outperform house brokers' profit forecasts for FY 2024 due to the departure of the CEO and CFO in the second half, as well as other unexpected departures that may or may not have contributed to the CEO's exit. There on a run rate basis will reduce costs by a further 800k per year.

We are entering the selling season, October to April. If Cambridge Cognition secures a few large contracts, which historically they have done every year for the last 5 or 6 years, the company will be extremely well-positioned.

[johndoe23] 11/10/2024 09:23

Yep, unfortunately like so many on AIM

[bedford1976] 11/10/2024 09:21

Well they might get a shock when they end up in the real world

[phowdo] 11/10/2024 08:02

Its a lifestyle business. Always has been.
It exists to fund the directors' lifestyles at your expense.

[bedford1976] 10/10/2024 19:20

Yes indeed I concur with your thoughts here I cannot possibly see this staying independent much longer. The market capitalization is now ridiculous.

[jasperlachat] 10/10/2024 18:16

The company is already up for sale with current SP!!! No idea if Stork got a payoff or not but this is the only news we get for our additional investment.

[bedford1976] 10/10/2024 17:55

I think we are at the stage where the board of directors need to put the company up for sale.

[cerrito] 10/10/2024 16:04

I am missing something Jasperlachat. Where did you get the info on the payoff to Stork.??

[jasperlachat] 10/10/2024 15:32

Nice of the company to rob us of money at the placing. Thought it was to increase sales growth, rather than to pay off the CEO.

[bmcollins] 27/9/2024 00:35

@40 Fathoms
This was indeed a useful reminder about Monument and the patent position sounds a very hopeful income stream going forward.
Thanks for this summary it's much appreciated.

[40 fathoms] 27/9/2024 00:19

Just a reminder we hold an @25% position in Monument Therapeutics and a double digit royalty on all revenue.

A bit of news below from the second arm they are developing in Neuroinflammation. As an aide-mémoire the more advanced arm (going in to a large trial next year) is a procognitive therapeutic for use in a subset of Schizophrenia.

"Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the United Kingdom Intellectual Property Office (“IPO”) has granted UK patent GB2616923, in support of MT1980, an anti-neuroinflammatory compound using novel brain-targeting technology.

The patent, which is set to provide exclusivity until at least 2044, secures the intellectual property rights for MT1980 as a treatment for clinical indications associated with neuroinflammation, such as Alzheimer’s disease, post-operative cognitive dysfunction and Long COVID. The unique absorption profile of MT1980, achieved using LipiCoreTM, a targeted oral drug delivery technology platform developed by TRx Biosciences and exclusively licensed to Monument Tx for MT1980, resolves blood-brain-barrier penetration limitations that exist with standard on-market formulations of the compound.

“The granting of this patent represents a significant achievement in our research and development efforts,” said Jenny Barnett, Chief Executive Officer of Monument Therapeutics. “MT1980’s innovative approach to targeting neuroinflammation positions us at the cutting edge of therapeutic advancement in psychiatry and neurology. We believe this compound has the potential to address significant unmet medical needs and our team is excited to advance MT1980 through the next stages of clinical development.”

Dr Robin Bannister Chief Executive Officer of TRx Biosciences said, “TRx is delighted to see this first grant of a therapeutic composition derived from our LipiCoreTM platform and continues to support Monument in its efforts to progress the MT1980 programme.”

In preclinical studies to date, MT1980 has shown significant brain uptake and strong anti-inflammatory activity across a panel of key biomarkers, with Phase I clinical data demonstrating an excellent safety profile and presence of drug in cerebrospinal fluid. Monument Therapeutics now plans a further Phase I multiple dosing study with MT1980, in addition to evidence of anti-neuroinflammatory effects in the brain."

[bmcollins] 24/9/2024 11:35

We holders have had a pretty dismal September so far, I have to admit to being surprised how bad it has been, still we are in AIM I guess !

[w t tutte] 12/9/2024 23:45

Here is what I suspect might have happened.

1) In January we had the appointment of 2 experianced NEDs both of whom have run listed businesses.
2) They quickly worked out that the CFO was not up to the task and tapped him to move on.
3) After the CFO departed they have turned their focus to the CEO.
4) They either identified somethings that felt were not up to scratch and the board tapped him as well or the CEO did not like increased level of scrutiny and has left in a fit of pique.

Land a big contract or two and this will soon be water under the bridge.

[bedford1976] 12/9/2024 20:05

Stork had 1.3 million share options so that removes a hefty lump, and quite frankly he was not worth 430k + all these options and bonuses he entailed.
On reflection his removal looks a beneficial for a leaner commercial business focus.

[earwacks] 12/9/2024 15:51

Fairly normal protocol to thank the exiting CEO even if it is with a boot up the derrière. Listening to Dr Bartlet interviews you can hear the unmistakable enthusiasm for the explosive developments in neuro science and medicines in the next couple of years.

[bmcollins] 12/9/2024 15:50

So am I, but I always feel suspicious when a CEO or CFO leave abruptly.
Perhaps my averaging this pm was not such a bad idea, time will tell.

[jasperlachat] 12/9/2024 15:44

I’m pleased for the kind words - anything else would be of concern.

[40 fathoms] 12/9/2024 15:41

I see it as good news.

He wasted the cash from the COVID related business surge by over hiring and then he overpaid for the Winterlight transaction. He oversaw the hiring of the pervious CFO who was clearly not up to the job. He put in place, the frankly terrible, Claret Loan note with the ridiculous options attached to it. Unforgivably the cost of the last capital raise was more than 15% of the amount raised. He allowed the previous Business Development lead to resign and took a year to hire a replacement. He has been very poor with the IR activities, in fact they have gone backward over the last few years.

While he had a number of admirable qualities he was not suited to running a listed business. Thankfully, he is not crucial to the, scientific team, nor the operations team and nor the marketing team. His loss maybe felt is on the IT integration and AI exploration side of things. They appointed a director with experience in this area in February so they should have some cover.

[nchanning] 12/9/2024 15:31

He was thanked and praised and extensively in the RNS...

[bmcollins] 12/9/2024 15:27

@40 Fathoms
I completely agree with you hence my earlier post said "this does not sound like good news", nevertheless we are where we are so I did buy a few more this afternoon but not, I confess, with much conviction...